EP2748328A4 - Peg-interferon lambda 1 conjugates - Google Patents
Peg-interferon lambda 1 conjugatesInfo
- Publication number
- EP2748328A4 EP2748328A4 EP12825651.8A EP12825651A EP2748328A4 EP 2748328 A4 EP2748328 A4 EP 2748328A4 EP 12825651 A EP12825651 A EP 12825651A EP 2748328 A4 EP2748328 A4 EP 2748328A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- conjugates
- peg
- interferon lambda
- interferon
- lambda
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
VN201102222 | 2011-08-25 | ||
PCT/US2012/027317 WO2013028233A1 (en) | 2011-08-25 | 2012-03-01 | Peg-interferon lambda 1 conjugates |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2748328A1 EP2748328A1 (en) | 2014-07-02 |
EP2748328A4 true EP2748328A4 (en) | 2015-03-04 |
Family
ID=47746747
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12825651.8A Withdrawn EP2748328A4 (en) | 2011-08-25 | 2012-03-01 | Peg-interferon lambda 1 conjugates |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP2748328A4 (en) |
JP (1) | JP2014525939A (en) |
CN (1) | CN103228792A (en) |
AU (1) | AU2012299423A1 (en) |
BR (1) | BR112014004302A2 (en) |
CA (1) | CA2846092A1 (en) |
RU (1) | RU2014111179A (en) |
WO (1) | WO2013028233A1 (en) |
ZA (1) | ZA201401159B (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3416675T3 (en) * | 2016-02-19 | 2021-10-11 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection with interferon lambda |
EP3375452B1 (en) | 2017-03-16 | 2025-01-08 | Evangelos Andreakos | Use of lambda interferons in the treatment of an obesity-related disorder, atherosclerosis or a coagulation disorder |
RU2678332C1 (en) * | 2017-09-08 | 2019-01-28 | Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "СФМ") | Pegylated interferon lambda with high bioaccessability in oral use and method for production thereof |
CN112245570A (en) | 2019-07-22 | 2021-01-22 | 厦门特宝生物工程股份有限公司 | An interferon-based treatment for diseases |
AU2022209506A1 (en) | 2021-01-21 | 2023-09-07 | Biosteed Gene Transformation Tech. Co., Ltd. | Method and pharmaceutical combination for preventing cancer recurrence |
CN117255695A (en) | 2021-01-21 | 2023-12-19 | 厦门特宝生物工程股份有限公司 | Cancer treatment method and pharmaceutical composition based on interferon |
WO2024121424A1 (en) | 2022-12-09 | 2024-06-13 | Daniel Zagury | Composite aids vaccine generating anti-hiv specific neutralizing antibodies and/or anti-hiv cytotoxic t cells |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
CN1176137C (en) * | 2002-01-15 | 2004-11-17 | 泛亚生物技术有限公司 | Multi-arm fork type functional polyethylene glycol preparation method and its application in medicine |
CN1927388B (en) * | 2004-09-10 | 2011-02-02 | 北京金迪克生物技术研究所 | Medicinal composition containing human interferon |
CN101247821B (en) * | 2005-06-03 | 2013-01-23 | Ambrx公司 | Improved human interferon molecules and their uses |
DK1931704T3 (en) * | 2005-10-04 | 2011-03-14 | Zymogenetics L L C | Generation and Purification of IL-29 |
CN101002942B (en) * | 2007-01-08 | 2010-07-21 | 湖南大学 | A kind of PEGylated liposome nanoparticle |
CN103536906A (en) * | 2008-06-05 | 2014-01-29 | 津莫吉尼蒂克斯公司 | Use of pegylated Type III Interferons for the treatment of hepatitis C |
-
2012
- 2012-03-01 JP JP2014527142A patent/JP2014525939A/en not_active Withdrawn
- 2012-03-01 WO PCT/US2012/027317 patent/WO2013028233A1/en unknown
- 2012-03-01 BR BR112014004302A patent/BR112014004302A2/en not_active IP Right Cessation
- 2012-03-01 AU AU2012299423A patent/AU2012299423A1/en not_active Abandoned
- 2012-03-01 CA CA2846092A patent/CA2846092A1/en not_active Abandoned
- 2012-03-01 EP EP12825651.8A patent/EP2748328A4/en not_active Withdrawn
- 2012-03-01 CN CN2012800033678A patent/CN103228792A/en active Pending
- 2012-03-01 RU RU2014111179/10A patent/RU2014111179A/en not_active Application Discontinuation
-
2014
- 2014-02-14 ZA ZA2014/01159A patent/ZA201401159B/en unknown
Non-Patent Citations (3)
Title |
---|
AHAD ET AL: "Interferon to PEG-Interferon: A Review", THE JOURNAL OFTEACHERS ASSOCIATIONRMC, RAJSHAHI, vol. 17, no. 2, 1 December 2004 (2004-12-01), XP002734715 * |
MUIR ANDREW J ET AL: "Phase 1b Study of Pegylated Interferon Lambda 1 With or Without Ribavirin in Patients with Chronic Genotype 1 Hepatitis C Virus Infection", HEPATOLOGY, vol. 52, no. 3, September 2010 (2010-09-01), pages 822 - 832, XP002734714, ISSN: 0270-9139 * |
See also references of WO2013028233A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP2748328A1 (en) | 2014-07-02 |
ZA201401159B (en) | 2015-04-29 |
CN103228792A (en) | 2013-07-31 |
BR112014004302A2 (en) | 2017-06-20 |
AU2012299423A1 (en) | 2014-03-06 |
WO2013028233A1 (en) | 2013-02-28 |
CA2846092A1 (en) | 2013-02-28 |
RU2014111179A (en) | 2015-09-27 |
JP2014525939A (en) | 2014-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201401159B (en) | Peg-interferon lambda 1 conjugates | |
FR2971446B3 (en) | COIFF'RASOIR | |
GB201121094D0 (en) | Concept 58 | |
GB201120424D0 (en) | Concept 66 | |
GB201119762D0 (en) | Concept 65 | |
GB201117189D0 (en) | Concept 64 | |
GB201114556D0 (en) | Concept 42 | |
GB201114546D0 (en) | Concept 22 | |
GB201114511D0 (en) | Concept 7 | |
GB201114478D0 (en) | Concept 11 | |
GB201114480D0 (en) | Concept 9 | |
GB201114503D0 (en) | Concept 54 | |
GB201114486D0 (en) | Concept 6 | |
GB201114565D0 (en) | Concept 52 | |
GB201114564D0 (en) | Concept 51 | |
GB201114563D0 (en) | Concept 50 | |
GB201114562D0 (en) | Concept 48 | |
GB201114561D0 (en) | Concept 47 | |
GB201114560D0 (en) | Concept 46 | |
GB201114559D0 (en) | Concept 44 | |
GB201114558D0 (en) | Concept 43 | |
GB201114517D0 (en) | Concept 15 | |
GB201114557D0 (en) | Concept 4 | |
GB201114535D0 (en) | Concept 38 | |
GB201114550D0 (en) | Concept 30 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20140311 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20150203 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 11/00 20060101AFI20150123BHEP Ipc: C12P 21/04 20060101ALI20150123BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20151203 |